GlassScriptPhysician profile
Martha V White
NPI 1841200268
$3,911.08
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,641 · 2020: $1,245 · 2022: $24.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan INC. | $2,490.00 | 2019-2020 | |
| Octapharma USA, INC. | $281.49 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $253.62 | 2019 | |
| Kaleo, INC. | $138.12 | 2019 | |
| Glaxosmithkline, LLC. | $128.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $102.54 | 2019 | |
| Grifols USA, LLC | $85.80 | 2019 | |
| Shire North American Group INC | $68.09 | 2019 | |
| Genentech USA, INC. | $66.74 | 2019 | |
| Pfizer INC. | $62.16 | 2019 | |
| Bio Products Laboratory USA, INC. | $48.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.07 | 2019 | |
| Alk-Abello, INC | $32.68 | 2019 | |
| Phadia US INC. | $28.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.10 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $19.42 | 2019 | |
| Genzyme Corporation | $19.29 | 2019 | |
| Csl Behring | $17.29 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.